Antengene Secures USD 97 Million in Series C Round of Financing

The company will use the proceeds from the investment round to fund the continuing clinical development of its robust pipeline of hematology and oncology therapies, expanding in-house research and development capabilities

FREMONT, CA: Leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, Antengene Corporation, secured USD 97 million in a Series C funding round led by Fidelity Management & Research Company LLC, with participation from new investors including GL Ventures (an affiliate of Hillhouse Capital), GIC, and a large, reputable long-term investor. The round was also participated by existing investors Qiming Venture Partners and Boyu Capital.

"We appreciate the recognition and trust from these prestigious investment institutions. This round of financing has drawn support from among the world's world's largest asset managers, top-tier healthcare investors widely recognized in the capital markets, and strong continuous support from our existing investors. This is an important milestone to reinforce Antengene's capabilities to bring cutting-edge therapies to help patients with life-threatening diseases in the Asia Pacific regions and around the world." said Dr. Jay Mei, Founder, Chairman, and CEO of Antengene.

The company will use the proceeds from the investment round to fund the continuing clinical development of Antengene's robust pipeline of hematology and oncology therapies, expanding in-house research and development capabilities and strengthening the commercial infrastructures in APAC markets. The company has successfully made progress with its broad pipeline of six clinical-stage programs and six pre-clinical stage oncology assets.

ATG-010 (selinexor) is the first and only oral selective inhibitor of nuclear export (SINE) compound in the world. The U.S. FDA approved selinexor combined with low-dose dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM). ATG-008 (onatasertib) is a second-generation dual mTORC1/2 inhibitor presently studied in multi-regional clinical trials for the treatment of advanced hepatocellular carcinoma (HCC), as well as non-small-cell lung cancer (NSCLC), gynecological malignancies and other cancers as a single agent or in combination with an anti-PD-1 antibody.

ATG-016 (eltanexor) is a second-generation oral selective inhibitor of nuclear export protein XPO1 presently studied in myelodysplastic syndrome (MDS) as well as various types of solid tumors, such as colorectal cancer (CRC) and prostate cancer (PrC). The company's drug discovery team is also focused on the research and pre-clinical development of innovative small molecules, monoclonal, and bi-specific antibodies to treat cancer.